查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2137164

人類神經調節蛋白市場：全球市場預測，2026-2032

Human Neuregulin Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類神經調節蛋白市場將成長至 7.8015 億美元，複合年成長率為 19.39%。

主要市場統計數據
基準年 2025 2.2554億美元
預計年份：2026年 2.7073億美元
預測年份 2032 7.8015億美元
複合年成長率 (%) 19.39%

人類神經調節蛋白：執行摘要及市場背景

人類神經調節蛋白是指參與細胞間通訊、發育以及組織維持和修復的一類訊號蛋白。它們最受關注的功能包括透過與ErbB家族受體相互作用來調節心臟、神經、上皮和免疫相關過程。研究領域涵蓋基礎生物學、生物標記開發、再生醫學和治療探索。由於神經調節蛋白的異構體、受體組合、組織分佈以及生物效應會隨生理環境的變化而變化，該領域的研究仍然十分複雜。

生物學、轉化研究和監管複雜性正在重塑這一領域。

研究重點正從對神經調節蛋白訊號傳導的廣泛研究轉向更精確地闡明其異構體、受體行為以及情境依賴性後果。分子生物學、單細胞分析、類器官系統和生物標記科學的進步正在提高我們區分有益訊號傳導與疾病進展或不良組織效應相關反應的能力。轉化研究仍然依賴可重複的檢測系統、具有臨床意義的終點、嚴格的安全性評估以及對劑量、給藥方法和目標組織暴露的更清晰理解。

人工智慧在加速發現的同時，也提高了檢驗的門檻。

人工智慧可以透過整合多體學資料集、識別訊號模式、確定實驗標靶優先順序以及改進影像資料和縱向臨床數據的分析，為人類神經調節蛋白的研究提供支援。機器學習技術也可用於對患者亞群進行分類以及預測受體和訊號路徑反應。然而，有效利用人工智慧需要精心挑選的資料集、透明的模型評估、實驗室檢驗以及採取措施來解決因不同人群和疾病狀態下的抽樣異質性而導致的偏差。因此，人工智慧應該作為實驗和臨床檢驗的補充，而不是替代，以闡明相關機制。

北美、歐洲和亞太地區的研究重點各不相同。

北美地區生物醫學研究實力雄厚，心血管、神經和再生醫學領域的轉化研究也十分活躍。歐洲強調合作研究、標準統一和基於臨床的評估，而中東則透過跨機構夥伴關係和對先進醫學的投資來建構研究和醫療保健能力。非洲的研究重點在於感染疾病、腫瘤、心血管疾病和醫療保健系統，基礎設施和專業檢測的可近性仍然是重要的考量。亞太地區擁有極為活躍的研究環境，尤其是在中國、日本、韓國、澳洲和印度，同時該地區監管框架多樣化，對精準生物學的興趣也日益濃厚。拉丁美洲透過學術和臨床研究網路做出貢獻，其研究重點受區域疾病負擔、檢測能力和專業技術可近性的影響。

國際組織正在影響合作、標準和促進翻譯獲取。

東協合作可以支持區域研究協調，同時考慮到監管發展進展和檢測基礎設施的差異。金磚國家成員國擁有廣泛的科學和臨床基礎，但合作必須應對數據標準、資金籌措環境和技術取得等方面的挑戰。歐盟受益於跨境研究框架和通用的法律規範。七國集團（G7）國家擁有豐富的生物醫學專業知識、先進的臨床系統和政策影響力。海灣合作理事會（GCC）國家正透過機構投資和國際夥伴關係加強其在生命科學領域的能力。北約成員國有潛力透過其已建立的網路促進科學合作，儘管目前對人類神經調節蛋白的研究仍主要局限於私人生物醫學和醫療保健機構。

國家級能力涵蓋發現、臨床應用和基礎設施建設。

美國和加拿大在分子生物學、臨床研究和轉化醫學領域擁有強大的實力。英國、德國、法國、義大利和西班牙透過大學、醫院和跨境歐洲研究網路做出貢獻。中國、日本和韓國在生物技術、神經科學、腫瘤學和再生醫學研究方面擁有強大的項目，並得到先進的分析基礎設施的支持。印度正在其龐大而多元化的醫療保健體系中擴展生物醫學研究和臨床能力。澳洲透過國際合作的研究機構和強大的臨床科學做出貢獻。巴西和墨西哥是拉丁美洲的重要研究中心，而俄羅斯儘管擁有成熟的科學實力，但在合作、資源取得和研究整合方面仍面臨許多限制。在所有國家，進展都取決於檢測方法的標準化、患者數據的品質、專業設施以及負責任的臨床應用。

產業領導者應優先闡明機制、系統化生物標記和夥伴關係模式。

領導者必須先明確預期的生物學應用場景，並區分神經調節蛋白異構體、受體、組織和疾病背景。研發項目應利用正交檢測方法、高度人源化的模型以及與藥理學和安全性相關的早期生物標記。與學術機構、醫院、數據專家和監管專家建立夥伴關係，有助於更好地獲取疾病隊列和專業方法。各組織應建立人工智慧驅動分析的管治，包括資料來源、可重複性測試和獨立檢驗。區域策略應反映基礎設施、核准流程、資料保護和臨床實務的差異，而非依賴單一的全球研發模式。

調查方法：基於證據的人類神經調節蛋白研究整合

本執行摘要以所列市場主題為參考，整合了現有的生物醫學見解，探討了人類神經調節蛋白的生物學特性、研究應用、轉化應用、區域研究環境和技術趨勢。摘要採用定性分析方法，避免了市場規模估算、市場規模計算、市場佔有率、預測以及針對特定公司的聲明。區域、群體和國家層面的具體考慮反映了研究基礎設施、醫療保健系統、監管調整和生物技術活動的顯著差異。由於所提供的資料來源不包含數值資料，因此結論僅限於檢驗的科學和結構性觀察，而非定量的商業性評估。

人類神經調節蛋白的研究需要準確性、檢驗和全球適應性。

人類神經調節素的研究領域十分廣泛，涉及訊號生物學、組織修復、神經科學、心血管研究和精準醫學等多個面向。要取得進展，需要闡明其異構體和受體的複雜性，將分子層面的見解轉化為具有臨床意義的成果，並在嚴格的檢驗控制下應用人工智慧。區域合作、方法論的協調一致以及精心設計的夥伴關係可以加速研究成果的臨床應用，同時減少重複研究和不確定性。最穩健的策略很可能是將機制嚴謹性、生物標記驅動的開發、負責任的數據利用以及對當地科學和監管環境的適應性相結合。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 人類神經調節蛋白市場：依類型

  • 胜肽
    • 純化
    • 合成
  • 重組蛋白
    • 大腸桿菌表達
    • 哺乳動物起源

第8章：人類神經調節蛋白市場：依應用領域分類

  • 調查
    • 體外
      • 生物標記研究
      • 細胞訊號傳導
    • 體內
  • 治療用途
    • 循環系統
    • 神經病學
    • 腫瘤學
      • 乳癌
      • 肺癌

第9章：人類神經調節素市場：依最終用戶分類

  • 學術研究機構
    • 醫院
    • 大學
  • 受託研究機構
    • 臨床階段
    • 臨床前階段
  • 製藥和生物技術公司
    • 大型製藥企業
    • 中型生技公司
    • 中小型生技公司

第 10 章：人類神經調節蛋白市場：按地區

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第11章 人類神經調節蛋白市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章 人類神經調節蛋白市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第14章：公司簡介

  • Abcam plc
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Creative Biolabs Inc.
  • GenScript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA
  • RayBiotech Inc.
  • Sino Biological Inc.
  • Thermo Fisher Scientific Inc.

第15章 主要專家

Product Code: MRR-961F26FD7FD4

The Human Neuregulin Market is projected to grow by USD 780.15 million at a CAGR of 19.39% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 225.54 million
Estimated Year [2026] USD 270.73 million
Forecast Year [2032] USD 780.15 million
CAGR (%) 19.39%

Human Neuregulin: Executive Summary and Market Context

Human neuregulin refers to a family of signaling proteins involved in cell communication, development, tissue maintenance, and repair. Its best-studied roles include regulation of cardiac, neural, epithelial, and immune-related processes through interactions with ErbB-family receptors. Research activity spans basic biology, biomarker development, regenerative medicine, and therapeutic investigation. The field remains scientifically complex because neuregulin isoforms, receptor combinations, tissue distribution, and biological effects vary by physiological context.

Biology, Translational Research, and Regulatory Complexity Are Reshaping the Field

The landscape is shifting from broad investigation of neuregulin signaling toward more precise characterization of isoforms, receptor behavior, and context-dependent outcomes. Advances in molecular biology, single-cell analysis, organoid systems, and biomarker science are improving the ability to distinguish beneficial signaling from responses associated with disease progression or unwanted tissue effects. Translation remains dependent on reproducible assay systems, clinically meaningful endpoints, rigorous safety evaluation, and clearer understanding of dose, delivery, and target-tissue exposure.

Artificial Intelligence Accelerates Discovery While Increasing Validation Requirements

Artificial intelligence can support human neuregulin research by integrating multi-omics datasets, identifying signaling patterns, prioritizing experimental targets, and improving analysis of imaging and longitudinal clinical data. Machine-learning methods may also help classify patient subgroups and predict receptor or pathway responses. However, useful deployment requires curated datasets, transparent model evaluation, laboratory confirmation, and protection against bias caused by uneven sampling across populations and disease settings. AI should therefore complement, rather than replace, mechanistic experiments and clinical validation.

Regional Research Priorities Differ Across North America, Europe, and Asia-Pacific

North America combines strong biomedical research capacity with active translational investigation in cardiovascular, neurological, and regenerative applications. Europe emphasizes collaborative research, harmonized standards, and clinically grounded evaluation, while the Middle East is developing research and healthcare capabilities through institutional partnerships and investment in advanced medicine. Africa's work is shaped by infectious disease, oncology, cardiovascular, and health-system priorities, with access to infrastructure and specialized assays remaining important considerations. Asia-Pacific includes highly active research environments, particularly in China, Japan, South Korea, Australia, and India, alongside diverse regulatory systems and growing interest in precision biology. Latin America is contributing through academic and clinical research networks, with priorities influenced by regional disease burdens, laboratory capacity, and access to specialized technologies.

International Groups Influence Collaboration, Standards, and Translational Access

ASEAN cooperation can support regional research coordination while accounting for differences in regulatory readiness and laboratory infrastructure. BRICS members provide a broad scientific and clinical base, but collaboration must address varied data standards, funding environments, and technology access. The European Union benefits from cross-border research frameworks and common regulatory structures. G7 countries contribute substantial biomedical expertise, advanced clinical systems, and policy influence. GCC states are strengthening life-science capabilities through institutional investment and international partnerships. NATO members may facilitate scientific collaboration through established networks, although human neuregulin research remains primarily a civilian biomedical and healthcare activity.

Country-Level Capabilities Span Discovery, Clinical Translation, and Infrastructure Development

The United States and Canada have extensive capabilities in molecular biology, clinical research, and translational medicine. The United Kingdom, Germany, France, Italy, and Spain contribute through university, hospital, and cross-border European research networks. China, Japan, and South Korea maintain strong programs in biotechnology, neuroscience, oncology, and regenerative research, supported by advanced analytical infrastructure. India is expanding biomedical research and clinical capabilities across a large and diverse healthcare system. Australia contributes through internationally connected research institutions and strong clinical science. Brazil and Mexico are important Latin American research centers, while Russia retains established scientific expertise alongside constraints related to collaboration, access, and research integration. Across all countries, progress depends on assay harmonization, patient-data quality, specialized facilities, and responsible clinical translation.

Industry Leaders Should Prioritize Mechanistic Clarity, Biomarker Discipline, and Partnership Models

Leaders should first define the intended biological use case and distinguish among neuregulin isoforms, receptors, tissues, and disease contexts. Development programs should use orthogonal assays, human-relevant models, and early biomarkers linked to pharmacology and safety. Partnerships with academic centers, hospitals, data specialists, and regulatory experts can improve access to disease cohorts and specialized methods. Organizations should establish governance for AI-assisted analysis, including dataset provenance, reproducibility testing, and independent validation. Regional strategies should reflect differences in infrastructure, approval pathways, data protection, and clinical practice rather than assuming one global development model.

Methodology: Evidence-Based Synthesis of Human Neuregulin Research

This executive summary uses the supplied market topic as a subject reference and synthesizes established biomedical knowledge about human neuregulin biology, research applications, translational considerations, geographic research environments, and technology trends. Insights are framed qualitatively and avoid market estimates, sizing, shares, forecasts, and company-specific claims. Regional, group, and country discussions reflect documented differences in research infrastructure, healthcare systems, regulatory coordination, and biotechnology activity. Because the source reference provided no numerical dataset, conclusions are limited to verifiable scientific and structural observations rather than quantitative commercial assessment.

Human Neuregulin Research Requires Precision, Validation, and Globally Adaptable Execution

Human neuregulin remains a multifaceted research area with relevance to signaling biology, tissue repair, neurological science, cardiovascular investigation, and precision medicine. Progress will depend on resolving isoform and receptor complexity, connecting molecular findings to clinically meaningful outcomes, and applying AI with strong validation controls. Regional collaboration, harmonized methods, and carefully designed partnerships can improve translation while reducing duplication and uncertainty. The most resilient strategies will combine mechanistic rigor, biomarker-led development, responsible data use, and adaptation to local scientific and regulatory conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Human Neuregulin Market, by Type

  • 7.1. Introduction
  • 7.2. Peptide
    • 7.2.1. Purified
    • 7.2.2. Synthetic
  • 7.3. Recombinant Protein
    • 7.3.1. E Coli Expressed
    • 7.3.2. Mammalian Expressed

8. Human Neuregulin Market, by Application

  • 8.1. Introduction
  • 8.2. Research
    • 8.2.1. In Vitro
      • 8.2.1.1. Biomarker Studies
      • 8.2.1.2. Cell Signaling
    • 8.2.2. In Vivo
  • 8.3. Therapeutic
    • 8.3.1. Cardiology
    • 8.3.2. Neurology
    • 8.3.3. Oncology
      • 8.3.3.1. Breast Cancer
      • 8.3.3.2. Lung Cancer

9. Human Neuregulin Market, by End User

  • 9.1. Introduction
  • 9.2. Academic Research Institutes
    • 9.2.1. Hospitals
    • 9.2.2. Universities
  • 9.3. Contract Research Organizations
    • 9.3.1. Clinical
    • 9.3.2. Preclinical
  • 9.4. Pharmaceutical Biotech Companies
    • 9.4.1. Big Pharma
    • 9.4.2. Mid-Size Biotech
    • 9.4.3. Small Biotech

10. Human Neuregulin Market, by Region

  • 10.1. Introduction
  • 10.2. Asia-Pacific
  • 10.3. North America
  • 10.4. Latin America
  • 10.5. Europe
  • 10.6. Middle East
  • 10.7. Africa

11. Human Neuregulin Market, by Group

  • 11.1. Introduction
  • 11.2. ASEAN
  • 11.3. GCC
  • 11.4. European Union
  • 11.5. BRICS
  • 11.6. G7
  • 11.7. NATO

12. Human Neuregulin Market, by Country

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. United Kingdom
  • 12.7. Germany
  • 12.8. France
  • 12.9. Russia
  • 12.10. Italy
  • 12.11. Spain
  • 12.12. China
  • 12.13. India
  • 12.14. Japan
  • 12.15. Australia
  • 12.16. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2025
  • 13.2. Market Concentration Analysis, 2025
    • 13.2.1. Concentration Ratio (CR)
    • 13.2.2. Herfindahl Hirschman Index (HHI)
  • 13.3. Recent Developments & Impact Analysis, 2025
  • 13.4. Product Portfolio Analysis, 2025
  • 13.5. Benchmarking Analysis, 2025

14. Company Profiles

  • 14.1. Abcam plc
  • 14.2. Bio-Techne Corporation
  • 14.3. BioVision, Inc.
  • 14.4. Creative Biolabs Inc.
  • 14.5. GenScript Biotech Corporation
  • 14.6. Lonza Group AG
  • 14.7. Merck KGaA
  • 14.8. RayBiotech Inc.
  • 14.9. Sino Biological Inc.
  • 14.10. Thermo Fisher Scientific Inc.

15. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Human Neuregulin Market, Years Considered for the Study
  • FIGURE 2. Global Human Neuregulin Market, Research Design
  • FIGURE 3. Global Human Neuregulin Market, Research Framework
  • FIGURE 4. Global Human Neuregulin Market, Data Triangulation
  • FIGURE 5. Global Human Neuregulin Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Human Neuregulin Market Size, by Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Human Neuregulin Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Human Neuregulin Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 9. Global Human Neuregulin Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Human Neuregulin Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 11. Global Human Neuregulin Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Human Neuregulin Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 13. Global Human Neuregulin Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Human Neuregulin Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 15. Global Human Neuregulin Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 16. Global Human Neuregulin Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Human Neuregulin Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Human Neuregulin Market Segmentation & Coverage
  • TABLE 2. Global Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 4. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Purified Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Purified Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Purified Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Synthetic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Synthetic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Synthetic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Recombinant Protein Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Recombinant Protein Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Recombinant Protein Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global E Coli Expressed Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global E Coli Expressed Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global E Coli Expressed Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Mammalian Expressed Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Mammalian Expressed Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Mammalian Expressed Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 23. Global Research Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Research Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Research Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global In Vitro Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global In Vitro Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global In Vitro Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Biomarker Studies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Biomarker Studies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Biomarker Studies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Cell Signaling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global Cell Signaling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global Cell Signaling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global In Vivo Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global In Vivo Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global In Vivo Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Therapeutic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Therapeutic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Therapeutic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Cardiology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Cardiology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Cardiology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 57. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 58. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 59. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 60. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Universities Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Universities Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Universities Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Clinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Clinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Clinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Pharmaceutical Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Pharmaceutical Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Pharmaceutical Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Big Pharma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Big Pharma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Big Pharma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Mid-Size Biotech Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Mid-Size Biotech Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Mid-Size Biotech Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Small Biotech Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Small Biotech Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Small Biotech Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 95. Asia-Pacific Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 96. Asia-Pacific Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 97. Asia-Pacific Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 98. Asia-Pacific Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 99. Asia-Pacific Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 100. Asia-Pacific Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 101. North America Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. North America Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 103. North America Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 104. North America Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 105. North America Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 106. North America Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 107. North America Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 108. North America Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 109. North America Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 110. North America Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 111. North America Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 112. North America Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 113. North America Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 114. Latin America Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Latin America Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 116. Latin America Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 117. Latin America Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 118. Latin America Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. Latin America Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 120. Latin America Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 121. Latin America Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 122. Latin America Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 123. Latin America Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. Latin America Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 125. Latin America Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 126. Latin America Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 127. Europe Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Europe Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 129. Europe Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 130. Europe Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 131. Europe Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 132. Europe Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 133. Europe Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 134. Europe Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 135. Europe Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 136. Europe Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 137. Europe Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 138. Europe Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 139. Europe Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 140. Middle East Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 141. Middle East Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 142. Middle East Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 143. Middle East Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 144. Middle East Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 145. Middle East Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 146. Middle East Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 147. Middle East Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 148. Middle East Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 149. Middle East Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. Middle East Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 151. Middle East Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 152. Middle East Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 153. Africa Human Neuregulin Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 154. Africa Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 155. Africa Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 156. Africa Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 157. Africa Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 158. Africa Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 159. Africa Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 160. Africa Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 161. Africa Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 162. Africa Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. Africa Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 164. Africa Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 165. Africa Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 166. Global Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 167. ASEAN Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 168. ASEAN Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 169. ASEAN Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 170. ASEAN Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 171. ASEAN Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 172. ASEAN Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 173. ASEAN Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 174. ASEAN Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 175. ASEAN Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 176. ASEAN Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 177. ASEAN Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 178. ASEAN Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 179. ASEAN Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 180. GCC Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 181. GCC Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 182. GCC Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 183. GCC Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 184. GCC Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 185. GCC Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 186. GCC Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 187. GCC Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 188. GCC Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 189. GCC Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 190. GCC Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 191. GCC Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 192. GCC Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 193. European Union Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 194. European Union Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 195. European Union Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 196. European Union Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 197. European Union Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 198. European Union Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 199. European Union Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 200. European Union Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 201. European Union Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 202. European Union Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 203. European Union Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 204. European Union Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 205. European Union Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 206. BRICS Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 207. BRICS Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 208. BRICS Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 209. BRICS Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 210. BRICS Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 211. BRICS Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 212. BRICS Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 213. BRICS Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 214. BRICS Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 215. BRICS Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 216. BRICS Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 217. BRICS Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 218. BRICS Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 219. G7 Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 220. G7 Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 221. G7 Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 222. G7 Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 223. G7 Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 224. G7 Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 225. G7 Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 226. G7 Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 227. G7 Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 228. G7 Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 229. G7 Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 230. G7 Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 231. G7 Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 232. NATO Human Neuregulin Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 233. NATO Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 234. NATO Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 235. NATO Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 236. NATO Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 237. NATO Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 238. NATO Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 239. NATO Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 240. NATO Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 241. NATO Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 242. NATO Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 243. NATO Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 244. NATO Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 245. Global Human Neuregulin Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 246. United States Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 247. United States Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 248. United States Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 249. United States Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 250. United States Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 251. United States Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 252. United States Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 253. United States Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 254. United States Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 255. United States Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 256. United States Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 257. United States Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 258. United States Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 259. Canada Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 260. Canada Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 261. Canada Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 262. Canada Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 263. Canada Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 264. Canada Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 265. Canada Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 266. Canada Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 267. Canada Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 268. Canada Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 269. Canada Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 270. Canada Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 271. Canada Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 272. Mexico Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 273. Mexico Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 274. Mexico Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 275. Mexico Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 276. Mexico Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 277. Mexico Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 278. Mexico Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 279. Mexico Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 280. Mexico Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 281. Mexico Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 282. Mexico Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 283. Mexico Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 284. Mexico Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 285. Brazil Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 286. Brazil Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 287. Brazil Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 288. Brazil Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 289. Brazil Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 290. Brazil Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 291. Brazil Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 292. Brazil Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 293. Brazil Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 294. Brazil Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 295. Brazil Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 296. Brazil Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 297. Brazil Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 298. United Kingdom Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 299. United Kingdom Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 300. United Kingdom Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 301. United Kingdom Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 302. United Kingdom Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 303. United Kingdom Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 304. United Kingdom Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 305. United Kingdom Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 306. United Kingdom Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 307. United Kingdom Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 308. United Kingdom Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 309. United Kingdom Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 310. United Kingdom Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 311. Germany Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 312. Germany Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 313. Germany Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 314. Germany Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 315. Germany Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 316. Germany Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 317. Germany Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 318. Germany Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 319. Germany Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 320. Germany Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 321. Germany Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 322. Germany Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 323. Germany Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 324. France Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 325. France Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 326. France Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 327. France Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 328. France Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 329. France Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 330. France Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 331. France Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 332. France Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 333. France Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 334. France Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 335. France Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 336. France Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 337. Russia Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 338. Russia Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 339. Russia Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 340. Russia Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 341. Russia Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 342. Russia Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 343. Russia Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 344. Russia Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 345. Russia Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 346. Russia Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 347. Russia Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 348. Russia Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 349. Russia Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 350. Italy Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 351. Italy Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 352. Italy Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 353. Italy Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 354. Italy Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 355. Italy Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 356. Italy Human Neuregulin Market Size, by In Vitro, 2017-2032 (USD Million)
  • TABLE 357. Italy Human Neuregulin Market Size, by Therapeutic, 2017-2032 (USD Million)
  • TABLE 358. Italy Human Neuregulin Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 359. Italy Human Neuregulin Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 360. Italy Human Neuregulin Market Size, by Academic Research Institutes, 2017-2032 (USD Million)
  • TABLE 361. Italy Human Neuregulin Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
  • TABLE 362. Italy Human Neuregulin Market Size, by Pharmaceutical Biotech Companies, 2017-2032 (USD Million)
  • TABLE 363. Spain Human Neuregulin Market Size, 2017-2032 (USD Million)
  • TABLE 364. Spain Human Neuregulin Market Size, by Type, 2017-2032 (USD Million)
  • TABLE 365. Spain Human Neuregulin Market Size, by Peptide, 2017-2032 (USD Million)
  • TABLE 366. Spain Human Neuregulin Market Size, by Recombinant Protein, 2017-2032 (USD Million)
  • TABLE 367. Spain Human Neuregulin Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 368. Spain Human Neuregulin Market Size, by Research, 2017-2032 (USD Million)
  • TABLE 369. Spai